{"entity":{"id":"nct05845450","kind":"trial","name":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","aka":[],"tldr":"A phase 2 trial of trastuzumab deruxtecan, durvalumab, panitumumab, botensilimab and other drugs in colorectal cancer, run by Gruppo Oncologico del Nord-Ovest, now recruiting.","summary":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) is a phase 2, interventional study registered as NCT05845450 by Gruppo Oncologico del Nord-Ovest, with a registry enrolment figure of 197 participants, started 2023-05-11 and due to reach its primary completion in 2027-05. Interventions recorded: Trastuzumab deruxtecan; Durvalumab; Panitumumab; Botensilimab; Balstilimab; Sotorasib; Vorbipiprant; Nivolumab; Amivantamab; Botensilimab; Balstilimab. Conditions listed: Colorectal Cancer; Resectable Colorectal Carcinoma. Primary outcome: major pathological response rate. Colorectal eligibility wording from the registry: \"* Histologically confirmed colorectal cancer adenocarcinoma that is judged as initially resectable with elective surgery aimed at radical intent with R0 margins as per multidisciplinary team assessment\". Sites: Italy. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05845450","url":"https://clinicaltrials.gov/study/NCT05845450"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["adc","checkpoint-inhibitor","kras-inhibitors","monoclonal-antibody"],"targets":[],"drugs":["trastuzumab-deruxtecan","durvalumab","panitumumab","botensilimab","balstilimab","sotorasib","nivolumab","amivantamab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05845450","phase":"2","setting":"Window-of-opportunity Umbrella Platform Trial of Short-course Pre-operative Targeted Treatments in Patients With Molecularly Selected and Resectable Primary Colorectal Cancer: the UNICORN Study","sponsor":"Gruppo Oncologico del Nord-Ovest","enrolled":197,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05845450/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/"},{"id":"balstilimab","kind":"drug","name":"Balstilimab","route":"/drugs/balstilimab/"},{"id":"botensilimab","kind":"drug","name":"Botensilimab","route":"/drugs/botensilimab/"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"panitumumab","kind":"drug","name":"Panitumumab","route":"/drugs/panitumumab/"},{"id":"sotorasib","kind":"drug","name":"Sotorasib","route":"/drugs/sotorasib/"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}